NGeneBio Resumes Trading on July 13, 2026 After Capital Reduction and Change Listing
NGeneBio has completed its capital reduction and change listing, with trading resuming on July 13, 2026.
The reduction in outstanding shares is expected to enhance per-share metrics such as EPS and book value.
This capital reduction is a defensive restructuring move to improve the balance sheet, without diluting existing shareholders.
[AI Summary]NGeneBio's trading suspension was lifted after completing a capital reduction. While the decrease in shares outstanding boosts per-share valuations, investors should monitor the company's turnaround progress given the underlying accumulated losses.
KOSDAQ Filing Information
Lifting of Trading Suspension of Stocks (Capital Reduction Stock Change Listing)